The Japanese Adverse Drug Event Report (JADER) database, a large, published database managed by the Pharmaceuticals and Medical Devices Agency for pharmacovigilance, collects spontaneous reports as a means to detect adverse events (AEs) related to drugs, and a newly published study used the JADER data to assess AEs related to the reference infliximab and to the biosimilar, CT-P13.
For inflammatory diseases, biosimilar infliximab CT-P13 (Inflectra, Remsima) has provided a more cost-effective option that has expanded access to biologic therapy in many nations, including Japan. The Japanese Adverse Drug Event Report (JADER) database, a large, published database managed by the Pharmaceuticals and Medical Devices Agency for pharmacovigilance, collects spontaneous reports as a means to detect adverse events (AEs) related to drugs, and a newly published study used the JADER data to assess AEs related to the reference infliximab and to the biosimilar.
In the study, published this month in the Journal of Pharmaceutical Health Care and Sciences, the researchers used data from 2014 (when the biosimilar launched in Japan) through 2018 and focused particularly on AEs related to infection. They identified 2771 reports of AEs (494 distinct events) related to the reference infliximab, and 402 reports of AEs (113 distinct events) related to the biosimilar.
Infection-related AEs accounted for 23.7% of reports for the reference infliximab and 21.9% of reports for the biosimilar. Among infection-related AEs associated with the reference, the most common was pneumonia, followed by interstitial lung disease, tuberculosis, and sepsis. Among infection-related AEs associated with the biosimilar, the most commonly reported AEs were pneumonia, followed by interstitial lung disease and sepsis.
Interestingly, write the authors, the reporting odds ratio (ROR) for infection with the biosimilar was 1.48 (95% CI, 0.7-3.13), while the ROR for infection with the reference drug was 3.54 (95% CI, 2.93-4.29); thus, the biosimilar was not associated with infection, while a signal was detected for the reference infliximab.
According to the authors, this observation may be because AE reporting was limited for the biosimilar versus the reference. If reports increase over time, the conclusion may also change, so more studies are warranted. The study was also limited by the fact that JADER data do not allow calculations for true incidence rates, and the fact that ROR does not provide a robust indication of signal strength.
“It is recommended that research be continued in order to accumulate a wide variety of information, and that newly reported data be placed in the multifaceted viewpoints for improvement of care levels,” write the authors.
Reference
Niinomi I, Hoshohata K, Mori Y, et al. Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database. J Pharm Health Care Sci. 2019;7(5):21. doi: 10.1186/s40780-019-0149-z.
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.